LLY Q2 Revenue Surges 48% to $23B, Retatrutide BLA Set for Q1 2027

Eli Lilly (LLY) reported Q2 2026 revenue of $22.97 billion, up 48% year over year, crushing estimates. The company raised full-year revenue guidance to $86 billion and disclosed that the retatrutide Phase 3 clinical data package is complete, with a BLA filing planned for Q1 2027. LLY closed at $1,157.93 with a market cap of $995 billion.

The numbers

• Revenue: $22.97 billion (+48% YoY)
• Mounjaro: $9.9 billion (+91%)
• Zepbound: $4.9 billion
• FY guidance: Raised to $86 billion
• Obesity franchise quarterly revenue: $14.8 billion (Mounjaro + Zepbound)
• Retatrutide: Phase 3 complete, BLA filing Q1 2027
• Foundayo (orforglipron): Approved April 2026, ramping

What the numbers mean

Lilly’s obesity franchise is generating $14.8 billion per quarter from Mounjaro and Zepbound alone. At an $86 billion annual revenue run rate, Lilly is on track to become the world’s largest pharma company by revenue. This was the fourth consecutive quarter of upward guidance revisions, signaling that GLP-1 demand is still accelerating, not plateauing.

The real story is not the earnings beat. It is the retatrutide timeline acceleration. With the complete Phase 3 package and a pre-approval access program now live, retatrutide could reach the market by mid-2027. The triple agonist (GLP-1/GIP/glucagon) has shown 26.6% placebo-adjusted weight loss and a 75% reduction in knee osteoarthritis pain. That efficacy approaches bariatric surgery levels.

The pre-approval access program is an aggressive move. It puts retatrutide in patients’ hands before FDA approval, builds real-world evidence, and applies competitive pressure on Novo Nordisk’s CagriSema, which has yet to report Phase 3 data. For context on the broader GLP-1 competitive dynamic, see our GLP-1 obesity market analysis.

Foundayo establishes the oral market

Foundayo (orforglipron), the only oral GLP-1 with no food or water restrictions, was approved in April 2026 and is now establishing the oral obesity market ahead of Novo Nordisk’s oral semaglutide. An oral GLP-1 that works without dosing restrictions is a meaningful convenience advance. The combination of Foundayo (oral daily) and retatrutide (injectable, monthly or less) gives Lilly three distinct obesity products targeting different patient segments.

Risk to watch

The specific risk is manufacturing capacity. Can Lilly produce enough supply for three blockbuster obesity drugs simultaneously? Mounjaro and Zepbound have already faced periodic shortages. Adding retatrutide to the production queue without adequate capacity planning could limit the launch trajectory. The pre-approval access program helps build supply data, but the real test comes at commercial launch.

Source: Eli Lilly Q2 2026 financial results

What It Means for the Trade

A 48% revenue print with a fourth consecutive guidance raise removes the last vestige of the “GLP-1 plateau” argument — the bears have been calling a demand ceiling for over a year, and Lilly keeps answering with numbers. But at a $995 billion market cap and $1,157.93, most of this is priced. The marginal information in this report is the retatrutide timeline: a complete Phase 3 package plus a Q1 2027 BLA filing plus a live pre-approval access program compresses the commercial timeline to roughly mid-2027. That is faster than the Street’s base case and keeps Lilly ahead of Novo Nordisk’s CagriSema, which has yet to report Phase 3.

The three-product structure is the moat. Foundayo owns the oral segment ahead of Novo’s oral semaglutide; Zepbound and Mounjaro hold the injectable incretin lead; retatrutide’s triple-agonist profile (26.6% placebo-adjusted weight loss, a 75% reduction in knee osteoarthritis pain) is positioned above both on efficacy. A competitor must now beat Lilly on efficacy, convenience, or price in every segment simultaneously. That is why the guidance raises keep coming.

Mechanism and Market Context

Retatrutide’s glucagon co-agonism is the mechanistic differentiator. Adding glucagon receptor activity to GLP-1/GIP increases energy expenditure and may improve body composition relative to dual agonists, which is why the 26.6% placebo-adjusted weight-loss figure approaches bariatric-surgery territory. The knee OA pain signal matters commercially as much as the weight number: it points toward indication expansion into cardiometabolic-adjacent conditions, the same playbook that turned semaglutide from a diabetes drug into a cardiovascular outcomes franchise.

The knee OA data deserves cross-trial caution — pain-reduction claims in orthopedic indications are notoriously placebo-sensitive, and the retatrutide figure has not been published in full. But the direction is consistent with meaningful weight load reduction, and it previews where the label expansion filings will go.

Risks and What Could Go Wrong

1. Manufacturing is the binding constraint. Three blockbusters plus a pre-approval access program on the same fill-finish and device supply chain is the single most credible bear argument on LLY; periodic Mounjaro and Zepbound shortages have already proven the bottleneck is real.
2. Payer and political pricing pressure on GLP-1s scales with the category — at $86 billion a year in revenue, the target on Lilly’s back grows with every guidance raise.
3. Retatrutide’s BLA is a filing, not an approval. The glucagon component carries a safety profile the FDA will examine closely; a label narrower than the Phase 3 hype would soften the launch.
4. Multiple compression. When a company is priced for near-perfection at $995 billion, execution stumbles get punished asymmetrically.

Own it for the franchise; do not confuse a guidance raise for new information at this valuation.